Biogen company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Acquired | Acquired

About Biogen

Biogen is an AD operator, providing a food waste recycling service for local authorities and commercial organizations. Food waste is collected from supermarkets, restaurants, manufacturers, and households. At its AD plant, the organic matter is depackaged and processed to produce biogas. The biogas is captured and fed into super-efficient gas engines to generate renewable electricity for the grid. What remains is a biofertilizer which is put back into the land to grow more crop.

Biogen Headquarters Location

Milton Parc Milton Ernest

Bedfordshire, MK44 1YU,

United Kingdom

+44 01234827249

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Biogen

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Biogen in 2 CB Insights research briefs, most recently on Aug 31, 2021.

Expert Collections containing Biogen

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Biogen is included in 1 Expert Collection, including Smart Cities.


Smart Cities

1,146 items

Biogen Patents

Biogen has filed 485 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Autoimmune diseases
  • Rare diseases
patents chart

Application Date

Grant Date


Related Topics




Medical imaging, Neuroscience, Neuroimaging, Psychiatric diagnosis, Magnetic resonance imaging


Application Date


Grant Date



Related Topics

Medical imaging, Neuroscience, Neuroimaging, Psychiatric diagnosis, Magnetic resonance imaging



Latest Biogen News

Despite failed trial, Brainstorm asks FDA to approve ALS drug

Aug 15, 2022

Published Aug. 15, 2022 Dive Brief: Brainstorm Cell Therapeutics, a New York-based drugmaker, plans to ask the Food and Drug Administration to approve an experimental treatment for amyotrophic lateral sclerosis that failed a key clinical trial in late 2020. In a statement Monday , Brainstorm’s CEO Chaim Lebovits said the decision was largely based on additional analyses of the trial, which uncovered an error in the statistical methods used to assess results for therapy, called NurOwn. Brainstorm’s move comes less than a month after the FDA agreed to review another ALS drug with a mixed track record. Developed by Biogen, the drug, known as tofersen, was found in a late-stage study to not be significantly better than a placebo at slowing the fatal neurodegenerative disease. Despite those results, Biogen requested approval based on the apparent effect its drug has on a protein that research suggests is a likely indicator of neurological damage. Dive Insight: Almost two years ago, Brainstorm revealed NurOwn, which is a type of engineered stem cell therapy, did not succeed in a placebo-controlled study meant to show its merit as an ALS treatment. While the NurOwn arm performed as Brainstorm had anticipated, the response rate seen in the placebo group was much higher than expected, ultimately causing the drug to miss the trial’s main goal. But Brainstorm now claims that, upon further evaluation and feedback from “key opinion leaders,” it believes there’s enough evidence to support an approval. For example, the company noted that a correction was made to published data from its late-stage study. The correction, Brainstorm claimed, meant NurOwn succeeded on a secondary goal — the average change on a rating scale that measures the severity of ALS symptoms — in a pre-specified subgroup of participants. In asking for approval based on a failed study, Brainstorm may present yet another challenge to the FDA office that evaluates new therapies for brain and nervous system disorders. That office, headed by agency veteran Billy Dunn , has been in the spotlight in recent years. Several times, it has reviewed high-profile applications that tested how flexible it could be toward drugs that haven’t been definitively proven effective, but target devastating diseases with few other treatment options. Its approvals of a Duchenne muscular dystrophy drug in 2016 and, more recently, Biogen’s medicine for Alzheimer’s disease have been especially controversial. Patients and advocacy groups have pressed the agency to be as flexible with potential therapies for ALS, given the dire nature of the disease, which is often fatal within two to five years after diagnosis. There are currently two drugs approved by the FDA to treat ALS, but the benefits they offer on function and survival are considered modest. More options may become available soon, however. The FDA is set to make an approval decision by Sept. 29 on an ALS drug called AMX0035, which was developed by Massachusetts-based Amylyx Pharmaceuticals and showed positive effects on function and survival in late-stage testing. And by Jan. 25, the agency should have a verdict on tofersen. Biogen has requested an accelerated approval that would hinge on the drug’s effects on “neurofilament light chain,” a protein that is of increasing interest in ALS research. According to Biogen, patients treated with tofersen experienced substantial reductions in the amount of this protein in their blood plasma. Brainstorm announced these updates alongside a second quarter earnings report that showed the company had a little over $12 million in cash, cash equivalents and short-term bank deposits as of June 30. Brainstorm expects that its existing cash, together with other funding activities and sales of its common stock, will be enough to fund operations for at least the next year.

  • When was Biogen founded?

    Biogen was founded in 2005.

  • Where is Biogen's headquarters?

    Biogen's headquarters is located at Milton Parc, Bedfordshire.

  • What is Biogen's latest funding round?

    Biogen's latest funding round is Acquired.

  • Who are the investors of Biogen?

    Investors of Biogen include Ancala Partners.

  • Who are Biogen's competitors?

    Competitors of Biogen include Healios.

You May Also Like

Biofourmis Logo

Biofourmis discovers, develops, and delivers clinically-validated, software-based therapeutics. Biofourmis has built Biovitals, a personalized, AI-powered health analytics platform that predicts clinical exacerbation in advance of a critical event, which is the backbone of its digital therapeutics product pipeline across multiple therapeutic areas, including heart failure, oncology, acute coronary syndrome, COPD, and chronic pain. It serves clients operating in the healthcare sector. The company was founded in 2015 and is based in Boston, Massachusetts.


Healios provides patients and doctors with mobile health platforms and Digital Biomarkers to improve patient diagnosis and treatment, research and clinical practice.

Roche Holding Logo
Roche Holding

Roche Holding is the holding company of F. Hoffmann-La Roche (Roche), a Swiss multinational research-focused healthcare company that discovers, develops and provides diagnostic and therapeutic products and services. Roche operates worldwide under two divisions: Pharmaceuticals and Diagnostics.

Helius Medical Technologies

Helius Medical Technologies is the medical device holding company in the business of innovation. The company's primary asset is NeuroHabilitation's PoNS device being developed for treatment of neurological symptoms caused by disease or trauma.

Novartis Logo

Novartis (NYSE: NVS) is a global healthcare company that provides solutions to address the evolving needs of patients worldwide. Focusing solely on healthcare, Novartis offers a diversified portfolio to meet these needs including medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools, and consumer health products.

Genentech Logo

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.